Here’s how to avert another baby formula crisis

Standing up new U.S. companies will take time. So let’s not rely solely on them.

Earlier this year, the FDA opened the U.S. market to overseas firms on an emergency basis, and on Sept. 30, it set a path for those companies to stay here permanently. Those that won approval, including Bubs Australia and Kendamil, will have until 2025 to come into full compliance with FDA rules on issues such as labeling. And the FDA will continue reviewing applications from companies that didn’t make it in during the initial process.

Past obstacles to foreign companies have also included tariffs (some of which were lifted during the shortage) and differences in regulations and nutritional requirements. If ever there were a time to resolve these differences, it’s now.